Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolute 303 in first-line metastatic pancreatic adenocarcinoma
NL-OMON61387Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- Sep 2026
- Modality
- Small Molecules, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in pancreatic adenocarcinoma (PDAC) comparing Daraxonrasib monotherapy, Daraxonrasib + gemcitabine + nab-paclitaxel and Gemcitabine + nab-paclitaxel (3 arms). Primary endpoints: Progression-free survival and Overall survival. Started Sep 2026; status: recruiting.
02
Drugs
daraxonrasibgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON61387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61387.